Achiko AG (SWX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) and PT Indonesia Farma Medis (“IFM”) have established a joint venture PT Achiko Medika Indonesia (“AMI”) for the production of its test platform developed, AptameX, a non-invasive DNA aptamer technology for Covid-19 detection in Indonesia.
Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX and companion health apps via its digital mobile health technology division, Teman Sehat. The AptameX DNA aptamer tests can be rapidly chemically synthesised, are cost-effective and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.
Its partner, IFM, is a medical device and pharmaceutical distribution company with a wide network of relationships and distribution channels covering hospitals, pharmacies and clinics throughout the main island of Indonesia.